Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Peking Union Medical College Hospital
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07108127CT.gov Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer | — | Recruiting | — | — | — |
NCT05672524CT.gov A Study of Tucatinib and Trastuzumab in People With Rectal Cancer | — | Recruiting | — | — | — |
NCT05515796CT.gov Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors | — | Completed | — | — | — |
NCT03365882CT.gov S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT02465060CT.gov Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | — | Active Not Recruiting | — | — | — |
NCT00004074CT.gov Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rectal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trastuzumab (this asset) | Peking Union Medical College Hospital | P2 | B · 60 |
| Capecitabine | Gustave Roussy, Cancer Campus, Grand Paris | P4 | BBB |
| Floxuridine | City of Hope Medical Center | P2 | BBB |
| Fluorouracilum | Gustave Roussy, Cancer Campus, Grand Paris | P3 | BBB |
| Oxaliplatin | Gustave Roussy, Cancer Campus, Grand Paris | P3 | BBB |
| Irinotecan | SCRI Development Innovations, LLC | P3 | BB |
| Cetuximab | Tang-Du Hospital | P2 | BB |
| Panitumumab | Grupo Espanol Multidisciplinario del Cancer Digestivo | P2 | BB |
| Pertuzumab | SWOG Cancer Research Network | P2 | BB |
+42 more in the Rectal Carcinoma cohort
Other indications for Trastuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 76 |
| Inflammatory Breast Carcinoma | — | P3 | BBB · 74 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trastuzumab in Rectal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trastuzumab-rectal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →